(SeaPRwire) –
Solid tumor immunotherapy has a dirty secret. For all the billions poured into checkpoint inhibitors, the patients who fail them — and there are many — hit a therapeutic wall fast. The anxiety hanging over ESMO 2026 in Madrid was precisely this: what comes after ICI failure in melanoma, ovarian cancer, and other hard-to-treat solid tumors? Immatics walked into that anxiety with an unusually confident answer. Not one drug. Not two. Three distinct clinical-stage programs, all aimed at a single intracellular target, PRAME. That is either disciplined portfolio design or expensive redundancy, and the new data from Dirk Schadendorf and Antonia Busse’s oral presentations begin to tell us which.
Start with the facts, because they are genuinely not trivial. IMA402, the company’s off-the-shelf TCR bispecific, was tested in 126 heavily pretreated patients — median three prior lines of therapy, median target lesion sum of 7.4 cm. This is not a cherry-picked, biomarker-lucky cohort. Within the recommended Phase 2 dose range of 10 to 45 mg, the confirmed objective response rate was 25% overall, climbing to 32% in PRAME-high patients across all indications and 32% specifically in melanoma. The numbers that matter more are the durability figures. In PRAME-high melanoma — where every single patient had already failed immune checkpoint inhibitors, a median of two prior ICI regimens — median duration of response hit 12.5 months, the longest ongoing response exceeded two years, and 91% of patients were alive at one year. Compare that to 60% one-year survival in patients dosed below the RP2D range, and the dose-response signal looks real rather than statistical noise. Safety held up too: transient lymphopenia and low-grade CRS, zero ICANS cases, no drug-related Grade 5 events, and no additive toxicity when combined with an ICI. Meanwhile, IMA203CD8, the PRAME-directed cell therapy, posted a 55% confirmed ORR with an 8.4-month median DOR in heavily pretreated gynecologic cancers at clinically relevant doses. Add the exploratory poster on anzu-cel’s Phase 1b melanoma cohort, and the “three complementary approaches” framing from CMO Cedrik Britten stops sounding like investor-relations boilerplate.
Now the commercial logic, which is where this gets interesting. Bispecifics and cell therapies are not redundant assets — they occupy different slots in the treatment algorithm. IMA402 is an off-the-shelf infusion, scalable, combinable with ICIs in melanoma and gynecologic cancers, and even stackable with Immatics’ own MAGEA4/8 bispecific IMA401 in lung cancer, with first data expected in 2027. IMA203CD8 plays the deeper-response, tumor-agnostic card for patients who can tolerate cell therapy logistics. The quiet strategic weapon here is the liquid biopsy-based PRAME testing. Rapid, sensitive patient selection is what turns a 25% unselected response rate into a 32% enriched one — and potentially a fast-to-market regulatory path in PRAME-high melanoma. That companion-diagnostic flywheel is exactly what separated winners from also-rans in the HER2 and PD-L1 eras. The end-game, if the data hold in Phase 2, is a company that doesn’t just sell a drug but owns the entire diagnostic-to-treatment loop for a target expressed across a wide swath of solid tumors. The risk is equally clear: PRAME-high enrichment must keep outperforming, or the three-program architecture becomes three parallel cash burns. Watch the ovarian expansion cohorts and the 2027 lung combination readout — those will decide whether Immatics built a franchise or just a very elegant hedge.